One day, two AstraZeneca deals

Share this article:

AstraZeneca expanded the footprint of its biologics arm MedImmune on Tuesday with two announcements: first, that it purchased Spirogen, a private biotech, for $440 million, and second that it joined up with ADC Therapeutics to develop two antibody drug conjugate (ADC) programs.

The ADC deal involves trading $20 million for an equity investment in ADC along with milestone payments. The linkage between the two deals is that Auven Therapeutics is the majority stakeholder in both ADC and Spirogen.

The deals follow AZ's August acquisition of Amplimmune as part of an expansive oncology push.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.